Keyword
in
Collection
Date
to
Houston Voice, No. 920, June 12, 1998
File 017
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 920, June 12, 1998 - File 017. 1998-06-12. University of Houston Libraries. University of Houston Digital Library. Web. May 27, 2020. https://digital.lib.uh.edu/collection/montrose/item/3055/show/3022.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1998-06-12). Houston Voice, No. 920, June 12, 1998 - File 017. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/3055/show/3022

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 920, June 12, 1998 - File 017, 1998-06-12, Montrose Voice, University of Houston Libraries, accessed May 27, 2020, https://digital.lib.uh.edu/collection/montrose/item/3055/show/3022.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 920, June 12, 1998
Contributor
  • Hennie, Matthew A.
Publisher Window Media
Date June 12, 1998
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 017
Transcript Woman wrongly diagnosed with AIDS loses lawsuit FORT WORTH. Texas — A woman who spent three years believing she was carrying the AIDS virus deserves no money from the doctors who treated her or the medical laboratory that tested her. a jury decided. Jurors voted 11-1 on June 4 to reject the negligence claim 29-year- old Khristol Watson of Denton brought against doctors Muddamalle Augustine of Arlington. Steven Sotman and Daniel Barbaro of Fort Worth and National Psycho pharmacology Laboratories, a now-defunct Tennessee company. Watson, who received the HIV-positive diagnosis in 1991, sued the doctors and the tab after discovering in 1994 that she does not carry the virus. She said he underwent a hysterectomy in 1993 largely because she believed she had the human immunodeficiency virus, which causes AIDS. Her attorneys had asked for damages up to $38 million for pain and suffering, lost earnings, medical expenses and mental anguish, includ ing Watson's distress at knowing she can no longer can bear children. The trial lasted four weeks. Jurors deliberated three days in Judge Dana Womack's 348th District Court before reaching a verdict. "I'm devastated," Watson told the Fort Worth Star-Telegram shortly after hearing the decision. "I've lost all my faith in the judicial system. It's not the money; it's the principle. "1 expected them to say something wrong happened because something very wrong happened." she said, but suggested she won't appeal the verdict. The doctors were pleased, their lawyers said. Henri Dussault. the lab's attorney, said it was clear jurors "took this very seriously and looked at all the evidence." Presiding juror David Beck. 36. said panel members couldn't determine who made the error in diagnosis. Without that, he said, the jury could award no damages. Augustine gave Watson the diagnosis in September 1991 based on an HIV-positive test after she checked into Willow Creek Hospital in Arlington for depression and substance abuse. Watson's suit contended her blood sample was switched or contaminated between the time the hospital drew it and labs in Tennessee and California tested it. Candidate refuses proclamation for rally LINCOLN, Neb. — Republican candidate for governor Mike Johanns was criticized last Tuesday by the state chapter of the American Civil Liberties Union for refusing as mayor to sign a proclamation for a gay pride rally. For the second straight year, Johanns rejected proclamations presented by Lincoln Pride Network, a local gay rights group. In a recent letter, the mayor told the group he would not grant their request because its PrideFest event conflicts with his religious belief. "I really view them as asking me to lend the credibility of the mayor's office and my own credibility to their gay pride event," Johann said last Tuesday. "I believe they are asking me to condone their lifestyle. I can't do that." Johanns said he could not endorse the group's call for "special rights" for gay and lesbian people. ZERir^stavudine) ZERIT* (stavudine) Capsules ZERIT* (stavudine) tor Oral Solution 10 USAGE ZERIT . stavudine) 11 indicdled lor lhe Ireatmenl at HIV* patients who lime receiver] prolonged prior jittovudme The (Juration al clinical Denelit 'rom anltretroviral may tie limited UM In the in vivo micronucleus assay, stavudme was clastogenic ir ... ng ir.ii stavudine administration lo m dosages ot 600 lo 2000 mgjyglttiy lor 3 days. 113 » jeoMm. Then. -ZEHTTIX *:th CD4 counts ol 50 to 500 i *.""> *tio lad re biws! it easi su dosages ol 40 mg BIO for patients weighing >60 kg. and 30 mg BID lor ihose weighing c60 kg The ndovudine dosage was 200 mg TID The study enroled 822 pawns with a medon baseline C04 count ol 235 cells/mm' (range 10 to 735 ceils/mm'), and a median du- ration Ol prior zidovudine treatment ot 88 weeks (range 11 to 356 weeks) Fourteen perceni ol sublets had AIDS al baseline. 50% had HIV-related symptoms and 36% were asymplomalic Table 1 gives the K,i plan-Meier estimates tor the lime lo disease progression tuses ota common skeletal ■,i,i''i;''M'-,'n-..;:n ■:", nr.r easis! ii ■.'..:: :i!B times tun I.:-; ■■<■■,:*, ...■ while no effeel was observed at 216 times human eiposure. A slight pusl-implantation loss ;,.:■, noted al 216 times tin tinman e.posure ,.,-;■ nt; effect ■ ■,:-.■: .::!;■:)..n atelv 135 tunes Mm human eipo- sure An increase m earV ral neonatal mortality 'birth lo 4 days ol age) neci-ned al 399 tares the human exposure while survival otneonales was unaffected at apOionrrialeiy 135 hmesthe human eiposurt A study in rals showed thai stavudine is transferred 10 lhe fetus Ihrough the placenla The concentration m fetal tissue was apprommately one-ha" should be i'.«l ■:..-■(■■; pregnancy or-iy ' ciearl1, reeded Table 1 Incidence ol Disease rogressiun First AIOS * Delimit! EmMvOfatti- ZERIT -idc-vudme 6 monlhs 4 4% 12 monlhs 104% IBmnnths 185% 24 months 26 6% ■ Kaplan-Ueiei esiimates, the oi stavudine and :idovudine was 57% 14.1% 23.3% 31.8% eraH difference between not significant Although it is no* * ■■■creted in human m:ik. there eusts the potential lor adverse eflects from stavudine m nursing infante Mi:" I ^continue nursing il they are receiving slavudine This is consistent with Ihe recommendation by Hie US Public health Service Centers lor Disease Con * troland Prevention lhal HIV-mfected mothers not breasl-leed Iheir m- fanls to avoid risking postnatal transmission of HIV. Use ol siavudme m pediatric patients is supported by evidence Irom adequate anil well-conlro-lea studies ol slavudine in adults mlhac ditional safety data m 115 pediatric av dala in 25 at ihese paiiems uq Lab Tesls AST (SGOT) , (-5 0 - ULN' ALT (SGPT) (<£ 0. Ul Bilirubin (>5.01 ULN) (<8.0 g/dL) Neutropenia (IWUtrochirS <750**mm** Thrombocytopenia (platelets <50.00Qm**m*) Stuff* AI45S-019- ZERIT zidovudine |40mgBID] (200mgTID) m=J12) (O--402) Amylase !4 13 (>14 . ULN] ' ThisaOnormalrly was reported in fewer Itian 1% ol patients 1 Data presented lor pane-tits ten whom laboratory evaluations were performed. '.*-:■:.r ]ut.i'icn ■'■ ;:a, ,dinellwatr, '9 :,■■■: mediation duration ol ndovudiiie therapy = 53 weeks ULN = tippet limit ot normal ic palienls and pharmacokinetic lents with clinically significant hy ■ I any 0' Ihe components contained in the formulation WWLMB The maior clinical toxicity ol ZERIT is peripheral nimOMIIty Din complication occuned in 19 and 24 percent ol Hie 11,TM palients with advanced HIV disease who received Ihe Iwo dose levels ol stavudine in Ihe Parallel Track Program In patient* will) less advanced HIV inleclion hi At iWnbl niMlfHIyi trial. peripheral imini-patHy nccurrtd in 13 percent el ZERIT Heal patients at eemur»< t» ** percewl mi nmtn -M KMMtorH ttr Bw * Pallenli wilh a history ol peripheral neuropalhy are at in ireaied risk lor the development of neuropathy II slavudine null be administered m Ihis clinical selling, careful monitoring CSf 210 3 he in evaluated in 25 HIV- jutric patients (age range 5 weeks to '5 years, weight 43 kg I alter IV and otal admioistralion of 0.125. 0 5 — - as single doses and as BID regimens The mean '-av*WlililywasT69i31.7%(n.?0| Peak p las - (C_| and area under the plasma concentrafion- he distribution o( stavudine into ) was assessed m 8 pediatric palients after ildosing The concentration of Slavudine in ranged lorm 0 008 to 0105 pg/mL al times ranging horn post-dose (dose ranging Irom 0125 tot mgAg) CSF is ranged Irom 16% to 125°a (mean, SO 0159"'. .35%| OVERDOSAGE [iper.ercfl .*.■•• adults tiea!*: .■.'■■ '.■"■■ ?■* Mnes It* t -commended M no acute tonicity Complications Olchionicoy ot known whether stavudine is eliminated by peritoneal dialysis or hemodialysis HOW SUPPLIED ZERIT" (stavudine) Capsules ate available in the following strengths PHECAUTIDNS jspiasmasa . __,. The lerminal eHmmation hart-kne alter oral or intravenous ad* ation of slavudine was apprommaiely one hour The mean i ii body clearance after intravenous infusion was 247 ± 94 i/m'. The mean - SD apparent oral clearance was 333187 mUrniivnv The percent of the Oose encrefed uncharged in ihe urtne was 34.5% after oral administration The clearance ol stavud-ne s related to bolt* body Surface area and body ■■veighi When josii ; kcohI'ikj v '.■-!■. wiqm :"ni:di ■'■■■: ■...'.-.■;■ in divided doses Pediatric patients weighing 30 kg ot greater should ADVERSE REACTIONS The major clinical '0-ocity ' .7£R * i.lavidicei , penptyra irripdlhy SM WARNINGS'section) Wilts: Peripheral neuropathy is dose related (see Table 21 Modesl elevation of hepatic fransaminases was also observed com ■ and configurations o plastic iw ■ i - ■ lrnmt Slrena-ft Shell Colt* Markmgi hi Canute Opium ClIlKklMl) (MrMM NDC Ho 15 mg L<jht yellow & dark ted BUS 1964 15 60 0003*1964-01 30 mg light btown BMS 1965 20 60 0003*1965*01 Dmg i:gt-■r.irg..' & BMS 1966 M 60 0003 1966-01 40mg Daikorange BMS 196? 10 60 0003*1967-01 Patients sti -it ZERIT s n/mrcaaiMKac 3r HIV mlec- Htv'nfectaiiiitcli-tJiiigoppoitunisficinleclions Patients should be advised to reman under the care of a physician when using ZERIT Palieflts should be mlormed lhal the most common toxicity of ZE 3iT is oeripfteral ieuiopatn> Symptoms ol pei pheral neurooa- ll-iy usually include tingling, burning, pain, or numbness in the hands or teet Palients shou a be ;ounseied 'hit this toncty occirrs with greater Itequency in patients with a history Of penpheril neu- ropathy They should be advised that these symptoms should he reported to theii physicians and mat dose changes may be necessary They should also be cautioned aCoul the use ol other medications lhat -nay enaceibale periphe'al neuropathy Caregivers ot young cWdten mrving ZERIT therapy should be n- slructed regarding detection and reporting at penptieral neuropathy. fjiienls should be . Isimed thai me long term etfei ■■, ol ZER t are unknown at Urns time They should be advised that ZERIT therapy has not been shown io reduce the risk of transmission of Hiv to others through seiuai contact or blood contamination Patients should be informed that the Cenier lor Disease Control £:DC) recommends lhat HIV-infected mothers nol nurse newOorn in* nts to reduce the nsk ot postnatal Iransmission ol HIV infection UtMtMlM -es eiAST (SGOT) arO ALT (SGFT} occured cam- -*-J! with continued "*— nt M Fertility Title 2 Peripheral Neuiopa1*i( Leading In Oose Modilicitioti % ZJRlT ndovudme :-H -i; Bid -250 r->g TID. (n=412) |it402} WM ru, Pragmi ZEHIT ZERIT mrngBDl ZOmHN (n,5M6) (n=5879) Grade 1-2 11 3 Grade 3-4 2 1 Total 13 4 20 17 4 2 24 19 Selected adverse events that occurred ■> i Suit patients receiving 2ER- ZERIT loi Oral Solution is a rtye-lree. truil flavored powder that piov-des 1 mg of stavudine per mL ol solution upon constitution wilh wafer Directions for solution preparation are included on the product label ZERIT lor ■ -.ild-iesistantcon- lainers that provide 200 mL of solution alter constitution wilh wafer (HOC No 0003*1968*01) ai controlled room temperature. ZERIT lor Oral Solution should be protected fiom eiusuivc moislure and stoied in tightly dosed containers al conlrollecl room temperature. 59* lo B6"F (J5* lo 30*C) After constitution, store tightly closed com., I I Del m a refrigerator. 36* to 46*F (2* to 8"C) Discard any unused portion after 30 days BRISTOL MYl'KN SQl II.Is ' | Immunology^ ' _____ Brawl M-o S-t-tt Comn-am tc activation i and increased ■nouse hbroblasl cells (con- •>'.■."*...■____■■- .-.*: ina .vrout "mmiolic actr.aliom % SludyAI455-019-' (40 mg BIO) |n*Jl2) 200 mg T10) (n*402) 54 49 Chiiiiffevei 40 Nausea and Vomiting 38 Ve'qm *-teaci'.'- ■'-,■■ Mt - 1*1,5 eveot *as reported n'ewt :i*..ii-1-. irfpMMi *-e-,ip*. -i: ;.-■■■: "His refusal io sign (the gay rally) proclamation is a clear Indication that he does not favor diversity if it includes gays and lesbians," said Matt LeMieux. director of the Nebraska chapter of the a^merican Civil Liberties Union. Johanns came under fire last year when he refused to sign a proclamation for the gay pride rally shortly after signing a proclamation in recognition of March for Jesus Day. Johanns signed a similar proclamation for the Christian event this year. Lesbian says attacks will not make her disappear BUFORD, S.C. — An area woman who was beaten twice in the past six months by people she said do not like her lesbian lifestyle vows not hide or let the attacks change her sexual ori entation. "People take offense that I don't hide it." Regan Wolf. 40. told The Charlotte (N.C.) Observer for a story last Monday. "They'd like for me to be a good little queer and slay in the closet. Well. I don't do that. Never have and never will." she said. Police are searching for the people who hit her on the head May 13. Wolf says she blacked out. Her live-in companion, Jenna Wolf, discovered Regan Wolf tied to the back porch rafters with a dozen or more slash marks on her back, police records said. "She was suspended, and her head was drooped over," Jenna Wolf, 31, said. Gay rights groups say Regan Wolf is a symbol of persecution. They demonstrated in Columbia in support of hate crime laws. "If ever there was a need for this type of legislation, this attack is a primary example of why," Wolfs mother, Jackie Adams, said al the rally. Regan Wolf said that on Dec. 26 she heard someone walking on the front porch of her mobile home, and when she opened the door she saw a stocky red-haired man with a scruffy beard. She said she was hit on the back of the head and blacked out. On the steps of her porch, in red spray paint, police found the phrase, "Jesus weren't born for you. faggot.'' Lancaster Sheriff Johnny Cauthen said his department has found no suspects. According to FBI statistics, 1,000 hate crimes againsl gays and lesbians were reported in 1996. Three of those were in South Carolina. Gainesville, Fla. Adds Gay Protection to Anti-Discrimination Law GAINESVILLE. Fla. — The Gainesville City Commission vote 3-1 on June 1 to add sexual orientation to the categories included in its anti-discrimination ordinance, alongside race, religion, marital status, and gender, The Gainesuide Sun reported. Il will now be a misdemeanor in the city to discriminate against gays and lesbians in the areas of housing, employ ment, lending and public accommodations. This brings us a lot closer to being a Justifiable community to live in," said Joe Antonelli. executive director of the North Central Florida AIDS Network. Gainesville Joins more than 100 other Florida city governments, including Key West, West Palm Beach and Tampa, wilh similar protections for gays. A leader of the oppo- siUoti lo the ordinance hinted that a legal challenge to the ordinance may be coming. —From staff and wire reports
File Name uhlib_31485329_n920_016.jpg